| Chronic Myelogenous Leukemia |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.59 |
| Patient Safety |
0 |
0.55 |
| Toxicology |
0 |
0.54 |
| Adverse Effects |
0 |
0.45 |
| Hospital |
0 |
0.45 |
| Leukemia |
0 |
0.9 |
| Lipids Management |
0 |
0.36 |
| Doppler Ultrasound |
0 |
0.31 |
| Blood |
0 |
0.27 |
| Cardiovascular Imaging |
0 |
0.25 |
| Biologic Therapy |
0 |
0.22 |
| Peripheral Artery Disease |
0 |
0.2 |
| Artery |
0 |
0.18 |
| Brachial |
0 |
0.18 |
| Clinical Research |
0 |
0.18 |
| Europe |
0 |
0.18 |
| Injury |
0 |
0.18 |
| Statins |
0 |
0.18 |
| Targeted Cancer Therapy |
0 |
0.18 |
| Tissue Doppler Imaging |
0 |
0.18 |
| Ultrasonography |
0 |
0.18 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Wound Management |
0 |
0.14 |
| Tyrosine Kinase Inhibitor |
0 |
0.13 |
| Hypertension |
0 |
0.12 |
| Antihypertensive Agents |
0 |
0.7 |
| Cardiovascular disease |
0 |
0.09 |
| Claudication |
0 |
0.09 |
| Electrocardiogram (ECG) |
0 |
0.09 |
| Femoral |
0 |
0.09 |
| Ischemia |
0 |
0.09 |
| LDL Cholesterol |
0 |
0.09 |
| Limb |
0 |
0.09 |
| Stenosis |
0 |
0.09 |
| Tyrosine Kinase |
0 |
1 |
| Electrophysiology |
0 |
0.07 |